The US District Court for the District of Rhode Island issues concerning ruling on drug patent settlements (Loestrin)

On September 4, 2014, Judge William Smith of the U.S. District Court for the District of Rhode Island issued a concerning ruling on drug patent settlements. In In re Loestrin 24 FE Antitrust Litigation, 2014 WL 4368924 (D.R.I., Sept. 4, 2014), Judge Smith misapplied the Supreme Court’s landmark decision in Federal Trade Commission (FTC) v. Actavis, 133 S. Ct. 2223 (2013), granting a motion to dismiss plaintiffs’ challenge to a settlement that had allegedly delayed generic entry. Facts The case involved Warner Chilcott’s Loestrin 24, a widely-used oral contraceptive. Direct purchasers (companies that purchased the drug directly from Warner Chilcott) and end payors (employee welfare benefit programs and three individuals) claimed that Warner Chilcott paid generics Watson (now known as

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Michael A. Carrier, The US District Court for the District of Rhode Island issues concerning ruling on drug patent settlements (Loestrin), 4 septembre 2014, e-Competitions September 2014, Art. N° 69705

Visites 3323

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues